Immunize.org supports evidence-based vaccination recommendations and schedules. Read more at About Us.
  • RSV (Respiratory Syncytial Virus)
  • RSV Preventive Antibody Recommendations for Infants

How do AAP’s September 2026 recommendations for the use of RSV preventive antibodies differ from CDC’s current clinical considerations?

The American Academy of Pediatrics (AAP) and CDC recommend nirsevimab or clesrovimab for eligible infants younger than 8 months in their first RSV season. This includes all infants not protected through effective maternal RSV vaccination. For the second season, both recommend only nirsevimab for eligible children age 8–19 months, regardless of maternal vaccination status or history of receiving antibody during their first RSV season.

CDC’s recommendations are limited to the narrow high-risk groups previously recommended to receive palivizumab (Synagis) and American Indian/Alaska Native children. The medically high-risk children on CDC’s list include those with chronic lung disease of prematurity with recent medical support, children with severe immunocompromise, and those who meet criteria for severe cystic fibrosis. AAP’s September 2026 policy expands second-season eligibility to a broader group of high-risk children with the following conditions, in addition to all those recommended for immunization by CDC:

  • Birth before 32 weeks’ gestation, regardless of ongoing support,
  • Hemodynamically significant congenital heart disease,
  • Pulmonary anatomic abnormalities or neuromuscular disorders that increase RSV risk,
  • Down syndrome or other chromosomal differences increasing risk, and
  • Chronic lung disease from significant neonatal conditions other than prematurity when medical support was needed during the preceding 6 months.

AAP’s updated 2026 schedule also explicitly addresses administration of repeat antibody doses after an eligible child undergoes antibody-depleting procedures after immunization. For details of AAP’s guidance, see https://doi.org/10.1542/peds.2026-079047, and https://downloads.aap.org/AAP/PDF/AAP-Immunization-Schedule.pdf. For CDC guidance, see www.cdc.gov/rsv/hcp/vaccine-clinical-guidance/infants-young-children.html.

Last reviewed: November 8, 2026

This page was updated on .